Diabetes Thought Leaders Join the Glooko Medical Advisory Board

Medical advisory board charged with helping to advance the Glooko unified diabetes management platform and advise Glooko on clinical studies

Palo Alto, Calif. ​ – July 9, 2015 ​ – ​Glooko Inc​., the leading unified platform for diabetes management, today announced the formation of its first Medical Advisory Board who will provide Glooko with clinical expertise in the area of diabetes analytics and clinical studies.

Comprised of a highly accomplished group of physicians from leading institutions across the United States, the Medical Advisory Board will share their extensive expertise in clinical engagement, diabetes devices, patient outcomes analytics, population management and other areas important to Glooko’s clinical studies, product development and strategic initiatives.

“As Glooko continues to deliver a unified platform for diabetes management, ​this board will be central in helping us to continue to deliver clinically relevant insights and outcome studies to drive increasing value to Provider Health Systems and the patients they serve”, said Rick Altinger, Glooko, CEO.

He continued, “We are thrilled by both the expertise and caliber of the members of our newly formed medical advisory board. Their complementary backgrounds and experiences, coupled with their expertise and innovative approaches to clinical practice will help to keep Glooko on the cutting edge.”

The five ­member board, chaired by Glooko’s Chief Medical Officer, Dr. Michael Greenfield, includes:

Dr. Mark Clements, MD, PhD -​ Associate Professor of Pediatrics, University of Missouri-­Kansas City School of Medicine, Children’s Mercy Hospitals, Kansas City, MO
Specializing in glucose variability, diabetes care technology and chronic complications in diabetes, Dr. Clements, MD, PhD and AAP fellow, brings a passion for data analytics and insights to his pediatric endocrinology practice at Children’s Mercy Hospitals and is known as a diabetes care innovator for the children he treats.

Dr. Jerome Fischer, MD­ – Diabetes and Glandular Disease Clinic (DGD), Clinical Instructor, University of Texas Health Science Center, San Antonio, TX

An accomplished researcher, partner and CIO of the DGD Clinic in San Antonio, TX, Dr. Fischer, MD has been involved as investigator in numerous research trials and is considered a leader in the most progressive use of diabetes education combined with technology and cutting-­edge treatments to serve diabetes patients in Southern Texas.

Dr. Michael Greenfield, ​MD -­ Glooko Chief Medical Officer, Endocrinologist, El Camino Hospital, Palo Alto, CA

Glooko Chief Medical Officer and diabetes technology expert, Dr. Greenfield, MD helps to lead the Glooko effort to create patient and clinical relevant and innovative analytics. Dr. Greenfield chairs the IRB at El Camino Hospital in Silicon Valley, completed his endocrine training at Stanford and is an accomplished researcher and a beloved clinician.

Dr. David Kerr, MD – Director of Diabetes Research and Innovation, Sansum Diabetes Research Institute, Santa Barbara, CA
Dr. David Kerr, MD is a UK trained physician and endocrinologist, a former diabetes ​ researcher at Yale and the former Editor of the Journal of Diabetes Science and Technology. Dr. Kerr is a Fellow of the Royal College of Physicians of Edinburgh, visiting Professor at Bournemouth University and has held a Gold Clinical Excellence Award from the National Health Service in the UK.

Dr. Howard Wolpert, MD -­ Director, Institute for Technology Translation, Joslin Diabetes Center & Associate Professor, Harvard Medical School, Boston, MA
A world­-renowned diabetes researcher and clinician, Dr. Howard Wolpert, MD has focused on the use of technology in intensive diabetes management. He established and directed the Insulin Pump & Continuous Glucose Monitoring Programs at the Joslin Clinic, and had been principal investigator in several multi­center randomized controlled trials. He is one of two foreign members of the Scientific Advisory Board of the European Union­-funded academic/industry collaborative on diabetes technology.

As Glooko’s international expansion continues we look forward to inviting several international thought leaders from around the globe to join the Glooko Medical Advisory Board.

With the decline of board certified endocrinologists, coupled with projected increases in diabetes population growth, the ability to care for diabetes patients is more and more falling on primary care and family care physicians. Through Glooko’s Population Management and Office Kiosk applications, endocrinologists and primary care physicians will have the data and insights they need to more efficiently and effectively treat patients with Type 1, Type 2 and gestational diabetes, enabling them to scale quality delivery of medical services, improve overall diabetes outcomes and ultimately lower the overall cost of serving the diabetes population.

This announcement comes on the heels of Glooko’s ​recent Series B investment ​that brought $16.5M of additional funds into the business. The investment will be used to fuel expansion of the Glooko platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms that enable both patient and provider decision support.

About Glooko
Glooko is the ​Unified Platform for Diabetes Management ​and provides an FDA-­cleared, HIPAA­-compliant Web and Mobile application for diabetes patients and clinicians which improves outcomes and lowers costs. The platform seamlessly unifies data from over 50 of the leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes­-centric analytics and supplies insightful reports, graphs and pattern­-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at​ https://glooko.com and follow us at ​Twitter.com/GlookoInc, and Facebook.com/Glooko.

Glooko PR Contact
Vikram Singh
[email protected]

Press Releases

Glooko in the News

Awards and Recognition